upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs. Psoriatic arthritis (PsA) in adults . >
JNNP: Comprehensive Clinical Motor Score as a Comprehensive Sensitive Prognostic Indicator for Parkinson's Disease
Time of Update: 2022-05-23
Parkinson's Disease Rating Scale (UPDRS) III ITEM6 dyskinesia scores, and predicted event PD in population-based studies (HR 1. 35, 95 %CI 1. 11 to 1. 67) . Another
BeiGene's Tislelizumab Approved for the Eighth Indication for Esophageal Squamous Cell Carcinoma
Time of Update: 2022-05-22
Screenshot source: NMPA official websiteTislelizumab is a humanized IgG4 anti-programmed death 1 (PD-1) monoclonal antibody designed to minimize binding to Fcγ receptors in macrophages .
Dupixent receives FDA priority review and is expected to gain new indications
Time of Update: 2022-05-22
S. Food and Drug Administration (FDA) has granted priority review status for the supplemental biological product application (sBLA) of the blockbuster IL-4/IL-13 inhibitor Dupixent (dupilumab).
The tertiary hospital issued a set of adopted drug assessment indicators: the proportion of use, the proportion of completion!
Time of Update: 2022-05-22
This extended indicator: the numerator is the number of varieties of the selected drugs that the hospital has completed the centralized procurement of drugs organized by the state in the purchase and sales contracts with volume .
Johnson & Johnson's "Daratumumab" new indication for listing
Time of Update: 2022-05-21
On April 15, the CDE official website showed that the new indication of Johnson & Johnson's daratumumab injection (subcutaneous injection) was applied for listing in China, and it is speculated that its indication may be multiple myeloma .
Anlotinib's fifth indication - iodine-refractory differentiated thyroid cancer officially approved
Time of Update: 2022-05-21
China's National Medical Products Administration (NMPA) officially approved Chia Tai Tianqing's Class 1 new drug for the treatment of patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) .
Chuxiong Prefecture in Yunnan has won 2 national geographical indication certification marks
Time of Update: 2022-05-20
A few days ago, the State Intellectual Property Office issued an announcement on the registration of certification
WuXi Junuo CAR-T product clinical application for new indications was approved
Time of Update: 2022-05-18
On April 20, WuXi Junuo announced that the clinical trial application of Ruikiolanza injection for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) has been approved.
European Radiology: When multiple primary lung cancers are diagnosed, what do different imaging signs indicate?
Time of Update: 2022-05-17
Recently, a study published in the European Radiology journal explored the relationship between the imaging classification, gene mutation status and surgical prognosis of sMPLC, providing a valuable reference for further treatment and evaluation of this type of patients .
Interpretation of ANCA indicators in the Department of Rheumatology and Immunology
Time of Update: 2022-05-14
. Following ethanol fixation of the neutrophil substrate, positively charged granule components rearrange around the negatively charged nuclear envelope, resulting in perinuclear fluorescence
BeiGene's CD3/CD19 Dual Antibody Belintoumumab New Indication Approved
Time of Update: 2022-05-14
Article source: Medical Cube Info>Author: info>On April 29, BeiGene's new indication of belintoumumab for injection submitted